

#### **Result Update**

April 30, 2018

# Rating matrix Rating : Buy Target : ₹ 870 Target Period : 12 months Potential Upside : 17%

What's Changed?	
Target	Changed from ₹ 760 to ₹ 870
EPS FY19E	Changed from ₹ 14 to ₹ 14.2
EPS FY20E	Changed from ₹ 14.4 to ₹ 16
Rating	Unchanged

Quarterly Performance											
₹ Crore	Q4FY18	Q4FY17	YoY (%)	Q3FY18	QoQ (%)						
Net premium	2541.8	2336.9	8.8	2386.8	6.5						
Total revenue	10052.3	10775.7	-6.7	9586.2	4.9						
PH Surplus	263.0	64.5	307.8	215.6	22.0						
PAT	381.2	336.0	13.5	230.3	65.5						

<b>Key Financial</b>	s			
₹ crore	FY17	FY18E	FY19E	FY20E
Premium	20853	25161	31702	39523
PH surplus	655	830	1235	1402
PAT	955	1151	1416	1597

Valuation summary										
	FY17E	FY18E	FY19E	FY20E						
P/E	78.0	64.7	52.6	46.7						
Target P/E	91.1	75.6	61.5	54.5						
P/EV	4.5	3.9	3.2	2.6						
Target P/EV	5.3	4.6	3.7	3.0						
RoNW	18.6	19.1	20.2	19.6						
VNB Margin	15.7	16.5	16.5	16.7						

Stock data	
Market Capitalisation	₹ 74495 crore
EV (Q4FY18)	₹ 19070 crore
AUM (Q4FY18)	₹ 11626 crore
VNB margin (Q4FY18)	16.2%
52 week H/L	774/628
Net worth	₹ 65278 crore
Face value	₹ 10
DII holding (%)	3.3
FII holding (%)	4.3

Comparative Return Matrix (%)										
	1M	3M	6M	12M						
SBI Life	15.0	11.8	NA	NA						
Ipru Life	12.6	0.3	11.5	8.0						
Max Financial	11.0	-5.7	-11.7	-20.8						

#### Research Analyst

Kajal Gandhi

kajal.gandhi@icicisecurities.com

Vishal Narnolia

vishal.narnolia@icicisecurities.com

Vasant Lohiya

vasant.lohiya@icicisecurities.com

# **SBI Life Insurance (SBILIF)**

₹ 745

# Focus on opex & persistency to drive margins...

- Premium growth continued to remain healthy at 21% YoY to ₹ 25350 crore in FY18 (₹ 9237 crore in Q4FY18), led by 30% YoY growth in individual new business and 31% YoY in renewals. Protection business witnessed improved traction at 23% YoY to ₹ 600 crore forming 5% of NBP.
- AUM growth is healthy at 18.9% YoY to ₹116262 crore.
- Opex grew 19.8% YoY to ₹ 860 crore. Higher top-line growth led to improvement in opex ratio to 9.3% in Q4FY18 vs 9.8% in Q4FY17.
- Unlike peers, SBILIF continue to build normal tax rate of ~15.5% for calculating EV. Adopting effective tax in future for calculating EV will be margin accretive and offer further upside than estimated.

#### Heathy growth with focus on linked and protection business

SBI Life reported highest NBP growth among top private insurers at 35.45% CAGR in FY15-17, thereby increasing its market share to 20.04%. Led by a strong distribution franchise, we expect SBI Life's NBP to grow at 22.4% CAGR in FY18-20E, thereby gaining market share to the extent of 200-300 bps by FY18-20E. Improvement in economic conditions and focus on HNIs is expected to keep proportion of ULIP at  $\sim$ 58% in FY18-20E, growing at 31% CAGR to ₹ 25170 crore in FY20E. We expect protection contribution to rise from  $\sim$ 5% in FY18 to  $\sim$ 8-9% in FY20E.

#### Strong bancassurance, high agent productivity to drive growth

SBI Life has a big advantage due to its tie-up with SBI, which has a network of ~24000 branches. In addition, one of the largest (1,08,000 as on March 31, 2018) and productive (individual NBP of ~₹ 2,58,000 per agent) agency network adds to the distribution strength. We expect healthy traction in bancassurance at ~25.7% CAGR in FY18-20E, keeping it as major contributor to individual NBP at ~64.8% in FY20E.

#### Improvement in persistency & cost efficiency to keep margins steady

SBI Life has reported a consistent improvement in persistency across periods (61st month persistency rose from 25.5% in FY13 to 58.4% in FY18). Improvement in persistency, focus on high margin products and cost control may increase VNB margins by 50 bps to 16.7% in FY20E.

#### Growth, cost control & persistency to drive profitability; maintain BUY

SBI Life has maintained growth trajectory in last three years along with focus on profitability. We expect ~23% CAGR in EV in FY18-20E to ₹ 28858 crore, driven by 28.5% CAGR in VNB to ₹ 2199 crore in FY20E. Operating RoEV is seen at ~20% by FY20E. Given strong distribution network and continued control of cost, we remain positive on the fundamental strength. Therefore, we revise our target price upwards at ₹ 870 (3x FY20E EV) valuing the stock on an appraisal basis (EV + structural value) with 1.5x FY20E EV + 20x FY20E VNB. Maintain **BUY** rating.



Exhibit 1: Financial summa	iry				
(₹ Crore)	FY16	FY17	FY18	FY19E	FY20E
New business premium	7106.5	10,143.8	10,972.5	13,433.6	16,432.2
APE	4878	6601	8428	10561	13166
Total premium	15665.5	20,852.5	25,160.5	31,702.2	39,522.8
PAT	844	955	1151	1416	1597
EV	12547.5	16,537.8	19,081.5	23,426.1	28,857.8
P/E (x)	80	71	59	48	42
P/BV (x)	14.3	12.2	10.3	9.0	7.7
P/IEV (x)	NA	4.1	3.5	2.9	2.3
RoEV (%)	NA	23.0	17.8	17.4	17.4

Source: SBI Life RHP, ICICI Direct Research

Variance analysis						
	Q4FY18	Q4FY18E	Q4FY17	YoY (%)	Q3FY18	QoQ (%) Comments
						Growth slower in Q4 though strong full year; improvement in market
First Year Premium	2,541.8	2,854.5	2,336.9	8.8	2,386.8	6.5 share seen
Renewal Premium	5,524.44	5,451.36	4,190.92	31.8	3,904.06	41.5 Healthy conservation ratio at 85% led to growth
						Higher single premium in Q4 led to moderate growth of 9.9% YoY in
Single Premium	1,223.9	1,156.3	865.6	41.4	525.2	133.0 NBP APE
Net Premium income	9,236.7	9,462.1	7,346.0	25.7	6,776.2	36.3
						Volatile equity market and elevated yield impacted investment incom
ncome from Investments	720.5	294.0	3,348.9	-78.5	2,793.8	-74.2 and simultaneously lowered acturial liabilities.
Total revenue	10,052.3	9,771.1	10,775.7	-6.7	9,586.2	4.9
Commission	375.9	326.0	283.2	32.8	312.4	20.3 Sequential improvement of $\sim$ 50 bps in commission ratio to
Operating expenses	484.2	664.3	434.8	11.4	439.7	10.1 Improvement in efficiency led to total cost ratio at 9.3%
Management Expenses	860.1	990.3	718.0	19.8	752.1	14.4
Benefits paid	3,501.3	3,498.0	2,659.8	31.6	2,913.8	20.2
Change in Actuarial Liability	5,258.5	4,000.0	7,232.0	-27.3	5,592.2	-6.0 Volatility in equity and rise in bond yields kept actuarial liabilities low
Total Expenses	9,789.3	8,568.0	10,711.2	-8.6	9,370.6	4.5
						Better experience in opex, lower actuarial liabilities led to increase in
Surplus/ (deficit)	263.0	1,203.1	64.5	307.8	215.6	22.0 surplus
Transfer to SH's A/c	355.8	403.1	312.2	14.0	125.9	182.7
Transfer from PH A/c	358.8	403.1	312.0	15.0	125.9	185.1
Investment income	114.1	97.7	89.0	28.1	118.3	-3.6
Profit/ (loss) before tax	389.2	448.8	332.2	17.1	240.5	61.8
						Healthy growth in premium and control on cost led to continued
PAT	381.2	348.8	336.0	13.5	230.3	65.5 traction in bottom-line
V NA-+						
Key Metrics	2 705 7	4.010.0	2 202 5	17.0	2.011.0	20.2
NBP	3,765.7	4,010.8	3,202.5	17.6	2,911.9	29.3
AUM ICV/*	116,260.0	117,594.1	95,830.3	21.3	113,175.0	2.7
IEV* *Company provides IEV on hel	19,070.0		16,540.0	15.3	18,082.0	5.5

\*Company provides IEV on half yearly basis. Source: Company, ICICI Direct Research

# source. Company, Total Direct Nesearch

Change in estimates						
		FY19E			FY20E	
		FILE			FIZUE	
(₹ Crore)	Old	New	% Change	Old	New	% Change
Premiums earned - Net	32,999.1	31,702.2	-3.9	41,350.0	39,522.8	-4.4
Total	43,998.4	42,588.3	-3.2	53,737.0	51,561.1	-4.0
Transfer to Shareholders'	1,214.6	1,234.9	1.7	1,206.1	1,402.4	16.3
PAT	1,401.3	1,415.6	1.0	1,435.5	1,596.5	11.2
EV	239.0	234.3	-2.0	291.2	288.6	-0.9
0 0 10101 D		,				

Source: Company, ICICI Direct Research


Assumptions							
		Current			Earlier		
	FY17	FY18	FY19E	FY20E	FY19E	FY20E	
NBP growth	42.7	8.2	22.4	22.3	21.2	21.3	
AUM growth	23.1	19.6	18.0	21.4	22.0	21.9	
EV Growth	0.0	15.3	22.8	23.2	23.1	21.8	



### **Company Analysis**


Exhibit 2: Healthy NBP growth continues led by traction in individual business											
NBP	FY15	FY16	FY17	Q1FY18	Q2FY18	Q3FY18	FY18	FY19E	FY20E		
Individual products	3,606	4,827	6,372	1,217	2,115	2,457	8,350	10,242	12,803		
Group saving products	1,493	1,649	3,284	494	249	319	2,020	3,192	3,630		
Protection products	430	630	487	102	140	149	600				
Total NBP	5,529	7,107	10,144	1,800	2,489	2,912	10,972	13,434	16,432		
Renewal premium	7,338	8,719	10,871	1,988	2,972	3,904	14,388	18,521	23,405		
Total premium	12,867	15,825	21,015	3,763	5,385	6,776	25,361	31,954	39,837		

Source: Company, ICICI Direct Research




Source: Company, ICICI Direct Research

Exhibit 4: Continued focus to keep cost in check bodes well for margin



Source: Company, ICICI Direct, Research

Exhibit 5: Strong NBP growth & cost efficiency to enable high VNB margins





Source: Company, ICICI Direct, Research

Exhibit 6: Lower actuarial liability keeps PH surplus higher QoQ....

Exhibit 7: ...expect  $\sim$ 17% CAGR in PH surplus in FY18-20E







Source: Company, ICICI Direct, Research

Source: SBI Life RHP, ICICI Direct, Research

Exhibit 8: Persistency ra Q4FY18	ntio (61 month) i	mpacted by	higher sing	le premium :	sees revival	in
Persisitency ratio %	FY15	FY16	FY17	Q2FY18	Q3FY18	Q4FY18
13th Month	79.3	80.7	81.1	77.5	78.4	82.3
37th Month	79.2	69.2	67.4	67.8	69.5	68.0
61th Month	40.7	53.8	67.2	51.1	54.0	58.6


Source: Company, ICICI Direct Research

Exhibit 9: Investment growth expected at 19.7% CAGR in FY18-20E										
FY17 Q1FY18 Q2FY18 Q3FY18 FY18 FY19E FY20E										
Shareholders' investments	4,296	5,241	4,994	5,152	5,223	6,004	7,005			
PH Fund Excl. Linked Assets	46,962	48,018	49,511	52,219	54,484	64,923	76,585			
Assets held to cover linked liabilities	44,573	46,185	48,823	52,436	54,936	64,381	80,715			
Total Investments	95,830	99,444	103,328	109,808	114,643	135,308	164,305			

Exhibit 11: Healthy premium growth to lead to higher RoE

Source: Company, ICICI Direct Research

#### Exhibit 10: EV growth led by incremental NBP and lower surrender



30 20 - 19.2 18.6 19.1 20.2 19.6 10 - 10 - 14.6

Q2FY18 Q3FY18

FY18

Source: Company, ICICI Direct, Research

Source: Company, ICICI Direct, Research


FY16

FY17

FY20E

FY19E





Source: Bloomberg, Company, ICICI Direct Research

Top 1	0 shareholders				
Rank	Name	Latest Filing Date	% O/S	Position (m)	Change (m)
1	State Bank of India	31-12-2017	62.10%	621.00M	+621.00M
2	BNP Paribas Asset Management Asia Limited	31-12-2017	22.00%	220.00M	+218.92M
3	MacRitchie Investments Pte. Ltd.	31-12-2017	1.95%	19.50M	+19.50M
4	Value Line Pte. Ltd.	31-12-2017	1.95%	19.50M	+19.50M
5	GIC Private Limited	31-12-2017	1.07%	10.72M	+10.72M
6	Reliance Nippon Life Asset Management Limited	31-03-2018	0.84%	8.36M	+0.15M
7	ICICI Prudential Asset Management Co. Ltd.	31-03-2018	0.56%	5.61M	+0.16M
8	Baron Capital Management, Inc.	31-12-2017	0.47%	4.70M	+4.70M
9	Aditya Birla Sun Life AMC Limited	31-03-2018	0.42%	4.23M	+0.43M
10	DSP BlackRock Investment Managers Pvt. Ltd.	31-03-2018	0.33%	3.29M	0

Shareholding Pattern										
(in %)	Mar-17	Jun-17	Sep-17	Dec-17	Mar-18					
Promoter	96.1	96.1	84.1	84.1	84.1					
FII			4.1	4.5	4.3					
DII			3.0	4.1	3.3					
Others	3.9	3.9	8.8	7.3	8.3					

Source: Reuters, ICICI Direct Research

,					
Recent Activity					
Buys			Sells		
Investor name	Value	Shares	Investor name	Value	Shares
State Bank of India	+6,765.05M	+621.00M	Janus Henderson Investors	-9.73M	-0.89M
BNP Paribas Asset Management Asia Limited	+2,384.87M	+218.92M	Kotak Mahindra Asset Management Company Ltd.	-4.80M	-0.46M
MacRitchie Investments Pte. Ltd.	+212.43M	+19.50M	BlackRock Investment Management (UK) Ltd.	-4.55M	-0.45M
Value Line Pte. Ltd.	+212.43M	+19.50M	HSBC Global Asset Management (India) Private Limited	-2.37M	-0.23M
GIC Private Limited	+116.81M	+10.72M	L&T Investment Management Limited	-2.38M	-0.23M

Source: Reuters, ICICI Direct Research



## **Financial Summary**

Exhibit 12: Policyholders Account					
(₹ Crore)	FY16	FY17	FY18	FY19E	FY20E
Premiums earned - Net	15665.5	20852.5	25160.5	31702.2	39522.8
Income from Investments	3340.9	9295.0	8456.3	10742.6	11894.0
Other income	19.7	67.4	68.6	75.4	83.0
Contribution from the Shareholders' account	93.7	62.7	75.6	68.1	61.3
Total	19,119.8	30,277.6	33,761.0	42,588.3	51,561.1
Commission	714.3	783.3	1120.7	1305.8	1649.8
Operating expenses	1480.9	1646.5	1719.4	2236.8	2788.6
Benefits paid (Net)	7958.5	9526.1	11712.0	13372.1	15930.6
Change in valuation of policy liabilities	7986.9	17241.0	17595.0	23570.9	28832.7
Others	7.4	24.1	5.5	6.6	7.9
Provision for tax	327.2	402.2	585.2	761.2	949.0
Surplus/(deficit) after tax	644.7	654.5	1023.2	1334.9	1402.4
Transfer to Shareholders' account	651.8	654.7	829.7	1,234.9	1,402.4

Source: SBI Life RHP, ICICI Direct Research

Exhibit 13: Shareholders Account					
(₹ Crore)	FY16	FY17	FY18	FY19E	FY20E
Amounts transferred from Policyholders' account	651.8	654.7	829.7	1234.9	1402.4
Income from investments	325.7	409.8	462.7	514.4	557.6
Total	977.5	1,064.5	1,292.4	1,749.3	1,960.0
Expenses other than insurance	28.7	27.1	32.0	35.2	42.3
Contribution to Policyholders' account	93.7	62.7	75.6	68.1	61.3
Others	3.0	4.0	7.4	4.0	4.0
Profit before Tax	855.2	974.7	1184.9	1646.0	1856.4
Provision for tax	11.0	19.9	34.1	230.4	259.9
PAT	844.2	954.7	1,150.8	1,415.6	1,596.5

Source: SBI Life RHP, ICICI Direct Research

Exhibit 14: Balance Sheet					
(₹ Crore)	FY16	FY17	FY18	FY19E	FY20E
Sources of Funds					
Share capital	1000	1000	1000	1000	1000
Reserve and surplus	3691	4465	5375	6485	7737
Credit/[debit] fair value change account	42	87	153	20	20
Networth	4733	5552	6529	7505	8757
Policyholders' funds	75991	93673	111434	135005	163838
Total Liabilities	80724	99225	118157	142804	172889
Applications of Funds					
Shareholders' investments	3565	4296	5223	6004	7005
Policyholders' investments	38256	46962	54484	64923	76585
Asset held to cover linked liabilities	36022	44573	54936	64381	80715
Loans	124	178	171	188	212
Fixed assets - net block	447	538	581	663	755
Net current assets	2311	2678	2761	6645	7615
Total Assets	80724	99225	118157	142804	172889

Source: SBI Life RHP, ICICI Direct Research



Exhibit 15: Key Ratios					
(Year-end March)	FY16	FY17	FY18E	FY19E	FY20E
Valuation					
No. of Equity Shares (Crore)	100.0	100.0	100.0	100.0	100.0
Diluted EPS (₹)	8.4	9.6	11.5	14.2	16.0
DPS (₹)	1.2	1.5	2.0	2.5	2.9
BV (₹)	47.3	55.5	65.3	75.1	87.6
EV per share	125	165	191	234	289
P/E	80.0	70.7	58.7	47.7	42.3
P/BV	14.3	12.2	10.3	9.0	7.7
P/IEV	NA	4.1	3.5	2.9	2.3
Efficiency Ratios (%)					
Commission expenses as a % of Gross					
Premium	4.5	3.7	4.4	4.1	4.1
Management expenses incl commission as a %	13.9	11.6	11.2	11.1	11.1
Return Ratios and capital (%)					
Return on Net worth	19.2	18.6	19.1	20.2	19.6
Opearating RoEV	NA	23.0	17.8	17.4	17.4
Solvency Ratio	212	204	200	195	200
Key Ratios (%)					
Conservation Ratio	81.7	81.4	84.2	82.2	81.4
VNB Margin		15.7	16.5	16.5	16.7
Surrender Ratio	4.7	5.7	5.3	4.9	4.7
Benefits paid as a % of Opening Liability	11.7	12.5	12.5	12.0	11.8
NBP (proportion %)					
Traditional	54.5	49.5	39.5	39.0	38.2
Linked	45.5	50.5	60.5	61.0	61.8

Source: SBI Life RHP, ICICI Direct Research

Exhibit 16: Key parameters					
(Year-end March)	FY16	FY17	FY18E	FY19E	FY20E
NBP	7,106.5	10,143.8	10,972.5	13,433.6	16,432.2
Growth (%)		42.7	8.2	22.4	22.3
Linked	3233.3	5122.9	6639.9	8191.2	10147.4
Growth (%)		58.4	29.6	23.4	23.9
Non Linked	3873.2	5020.9	4332.6	5242.5	6284.8
Growth (%)		29.6	-13.7	21.0	19.9
APE	4878.1	6600.9	8540.0	10561.2	13165.5
Growth (%)		35.3	29.4	23.7	24.7
VNB		1036.8	1390.0	1742.6	2198.6
Growth (%)			34.1	25.4	26.2
EV	12547.5	16537.8	19070.0	23426.1	28857.8
Growth (%)			15.3	22.8	23.2
AUM	77842.7	95830.3	114643.4	135308.1	164305.0
Growth (%)		23.1	19.6	18.0	21.4
PH Funds	74277.8	91534.8	109420.4	129304.0	157299.5
Growth (%)		23.2	19.5	18.2	21.7
SH Funds	3564.9	4295.5	5223.0	6004.2	7005.5
Growth (%)		20.5	21.6	15.0	16.7

Source: SBI Life RHP, ICICI Direct Research



#### RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock.

Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction;

Buy: >10%/15% for large caps/midcaps, respectively;

Hold: Up to  $\pm$ -10%; Sell: -10% or more;



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@ICICI Direct



#### ANALYST CERTIFICATION

We /l, Kajal Gandhi, CA, Vasant Lohiya, CA and Vishal Narnolia, MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a Sebi registered Research Analyst with Sebi Registration Number – INH00000990. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

It is confirmed that Kajal Gandhi, CA, Vasant Lohiya, CA and Vishal Narnolia, MBA Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

It is confirmed that Kajal Gandhi, CA, Vasant Lohiya, CA and Vishal Narnolia, MBA, Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.